Drug Lobby Driving PBS Changes, Says Expert (Australia)
This article was originally published in PharmAsia News
Australia's parliament is considering new amendments to the Pharmaceutical Benefits Scheme that will establish separate criteria for evaluating pricing of brand-name and generic drugs in Australia, and therefore affect Australian drug pricing. Australian National University expert Dr. Thomas Faunce says the amendments, if approved, will drive up brand-name drug costs. He notes that the proposed changes are backed by Australia's pharmaceutical lobby Medicines Australia. Faunce says the amendments would obviate current "reference pricing," which currently requires that new patented drugs first prove they are superior to existing products. (Click here for more
You may also be interested in...
ODAC's 17-18 June discussion of pediatric development plans for four investigational oncology agents will serve as a trial run of the technology platform and logistics for any future application-specific virtual advisory committee meeting, but without the stress associated with a pending application and a user fee deadline.
Vibostolimab is less advanced than Roche’s competing tiragolumab, but Merck thinks the combo of its anti-TIGIT and Keytruda will offer a better therapeutic profile.
Ambitious efforts to make the EU more resilient to future challenges, such as health threats, drug supply problems, scientific advances and growing medicine costs, have taken a step forward with the publication of a roadmap for a wide-ranging Pharmaceutical Strategy to be adopted by the European Commission later in the year.